By VETTAPHARMA reporter – Derek Roche: AstraZeneca reported total revenue of $15.3 billion in Q1 2026, reflecting an 8% year-on-year (YOY) increase, demonstrating continued growth across its core therapy areas.
Core earnings per share (EPS) increased 5% to $2.58, highlighting sustained profitability alongside revenue expansion. The company also reiterated expectations for mid-to-high single-digit revenue growth and low double-digit core EPS growth for full-year 2026.
What is working for the company
Performance in the quarter was driven by strong momentum in oncology, CVRM (cardiovascular, renal and metabolism), and rare diseases, supported by continued uptake of newer medicines and established blockbuster brands. The company’s strategy of combining innovative launches with lifecycle management of key assets continues to underpin growth.
AstraZeneca’s pipeline remains a major growth engine, with 4 new molecular entities under regulatory review, 21 in late-stage development, and 186 total projects, including 118 in Phase II/III, reinforcing long-term sustainability of revenue expansion.
Latest clinical trials driving future growth
The clinical trials appendix highlights several ongoing late-stage and high-value programmes, including:
- TROPION-Lung07, TROPION-Lung10, and TROPION-Lung12 (oncology, NSCLC)
- PACIFIC-4, PACIFIC-5, and ADRIATIC (lung cancer immunotherapy)
- eVOLVE-Lung02, eVOLVE-Cervical, and eVOLVE-Meso (volrustomig programmes)
- EvoPAR-Prostate01 and EvoPAR-Breast01 (saruparib, PARP1 inhibitor)
- WAYPOINT and EMBARK (Tezspire in respiratory diseases)
- ICAN trial (Ultomiris in IgA nephropathy)
Many of these programmes have data readouts expected in 2026 and beyond, with several pivotal Phase III trials ongoing, underscoring AstraZeneca’s strong late-stage pipeline depth.
Near-term growth outlook
The combination of ongoing Phase III readouts, regulatory reviews, and continued commercial uptake positions AstraZeneca for potential incremental growth in the coming quarters. Upcoming clinical data—particularly from oncology and specialty care programmes—could act as near-term catalysts, supporting both revenue acceleration and pipeline value creation.
Crossing the $15 billion quarterly revenue milestone, alongside 8% YOY growth, reflects a business model that is currently working through scientific innovation, strong execution, and pipeline productivity, with further upside expected as late-stage assets mature and approach commercialization.
